{
    "Trade/Device Name(s)": [
        "Anti-MCV\u00ae",
        "Anti-Mutated Citrullinated Vimentin IgG EIA"
    ],
    "Submitter Information": "ORGENTEC Diagnostika GmbH",
    "510(k) Number": "K092399",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052133"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OQZ",
        "NHX"
    ],
    "Summary Letter Date": "June 25, 2010",
    "Summary Letter Received Date": "July 1, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5775"
    ],
    "Regulation Name(s)": [
        "Rheumatoid factor immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-mutated citrullinated vimentin (MCV)",
        "IgG class autoantibodies"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Indirect solid phase enzyme immunoassay (ELISA)",
        "Semi-quantitative enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay",
        "ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ORGENTEC Anti-MCV\u00ae IgG EIA for detecting IgG autoantibodies against mutated citrullinated vimentin in serum as aid in RA diagnosis",
    "Indications for Use Summary": "Aid in the diagnosis of Rheumatoid Arthritis by qualitative and semi-quantitative measurement of IgG autoantibodies against mutated citrullinated vimentin in human serum, for in vitro diagnostic use in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}